Meda snaps up Jazz's women's business for $95M; Novartis wins FDA panel nod for CF drug;

 @FiercePharma: Roche figures it's safe from biosimilars for a few years longer, because of development delays. More | Follow @FiercePharma

> Jazz Pharmaceuticals ($JAZZ) plans to sell its women's health business, including the hormone-replacement gel Elestrin, to Swedish drugmaker Meda for $95 million. Report

> An expert panel recommended that FDA approve the Novartis ($NVS) drug TIP, an inhaled-powder version of its Tobi antibiotic for cystic fibrosis patients. Report

> FDA issued a warning letter to DPT Laboratories, citing sterility failures in a wound treatment, Santyl Ointment, and the company's response to those problems. Report

> Spectrum Pharmaceuticals wrapped up its acquisition of Allos Therapeutics and said it expects pro forma revenue of $300 million this year. Release

> United Drug plans to delist in Ireland and seek a listing in London. Report

> Catalent Pharma Solutions sold $350 million of senior notes in a private placement, $100 million more than initially expected. Report

> Standard & Poor's affirmed Valeant Pharmaceuticals' ($VRX) credit rating despite its plans to fund a $2.6 billion buyout of Medicis Pharmaceutical with debt. Report

Medical Device News

 @FierceMedDev: Sonitus turns to Europe for the commercial rollout of its new hearing aid. It transmits sound through teeth. Release | Follow @FierceMedDev

 @MarkHFierce: Whites are more likely to be treated with CRT-D therapy than blacks and Hispanics, according to a new study. Article | Follow @MarkHFierce

 @DamianFierce: Hologic has to fork over $4M after losing a patent suit to Smith & Nephew. News | Follow @DamianFierce

> Analysts: Medical device M&A will heat up in 2013. Story

> Study: Ariosa's Down syndrome molecular Dx works well in broader population. Item

Biotech News

 @FierceBiotech: HGS sharpens ax as restructuring claims 114 jobs. Item | Follow @FierceBiotech

 @JohnCFierce: Five down (as in 5 straight late-stage failures): Another Eli Lilly drug flunks a Phase III test. Article | Follow @JohnCFierce

> Zymeworks snags $11M, Merck milestone to fuel bi-specific antibody work. More

> Tufts: Cancer drugs win a speedier race to the FDA goal line. Story

> Merck KGaA grabs a cancer antibody hybrid in $625M Symphogen pact. News

Vaccines News

> University of Oklahoma advances work on West Nile vaccine. Item

> Low HPV vaccination rates spur calls for wider use. Article

> Dendritic cells raise questions about cancer vax effectiveness. More

> ImmusanT launches U.S. trial for celiac vax. News

Pharma Manufacturing News

> Sun recalls biosimilar used for treating brain bleeding. More

> Under regulatory cloud, CEO says Novartis must boost quality. Article

> Competitors' manufacturing screw-ups keep Fresenius busy. Story

And Finally... Fish oil seemed to help seniors build muscle strength when combined with strength training, a study found. Report

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.